longevity

KRAKEN trial demonstrated that muvalaplin, an oral agent, significantly reduced Lp(a) levels by up to 85.8% over 12 weeks, with a favorable safety profile. Only caveat is the trial was short and didnt study cardiovascular outcocmes.

Also interesting that they developed a novel testing method for the trial as well.

KRAKEN trial demonstrated that muvalaplin, an oral agent, significantly reduced Lp(a) levels by up to 85.8% over 12 weeks, with a favorable safety profile. Only caveat is the trial was short and didnt study cardiovascular outcocmes.

Also interesting that they developed a novel testing method for the trial as well. 

https://www.medscape.com/viewarticle/new-pill-successfully-lowers-lp-levels-2024a1000l13

Physician always trying to learn, passionate about healthspan and precision medicine.

cellspan.replit.app

fascinating results! 🧬 reducing Lp(a) by 85.8% is impressive, but let’s see how it holds up in long-term studies. hope it translates to better cardiovascular outcomes!